Cargando…

Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis

PURPOSE: The clinical significance and prognostic role of circulating plasma cells (CPCs) in multiple myeloma (MM) are still controversial. We conducted the first meta-analysis to clarify the correlation between CPCs and the clinicopathological features and prognosis of MM patients. METHODS: A compr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jia, Wang, Ningning, Tesfaluul, Nahom, Gao, Xiaojuan, Liu, Shuai, Yue, Baohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509371/
https://www.ncbi.nlm.nih.gov/pubmed/28704521
http://dx.doi.org/10.1371/journal.pone.0181447
_version_ 1783250013765238784
author Li, Jia
Wang, Ningning
Tesfaluul, Nahom
Gao, Xiaojuan
Liu, Shuai
Yue, Baohong
author_facet Li, Jia
Wang, Ningning
Tesfaluul, Nahom
Gao, Xiaojuan
Liu, Shuai
Yue, Baohong
author_sort Li, Jia
collection PubMed
description PURPOSE: The clinical significance and prognostic role of circulating plasma cells (CPCs) in multiple myeloma (MM) are still controversial. We conducted the first meta-analysis to clarify the correlation between CPCs and the clinicopathological features and prognosis of MM patients. METHODS: A comprehensive literary search for relevant studies was performed on PubMed, Embase, Medline, CNKI (Chinese) and Web of Science databases (January 1, 1950 to December 20, 2016). The associations between CPCs and survival rate and clinicopathological parameters, including International staging system (ISS) and Durie-Salm staging system (DS) stage, were evaluated. Then pooled hazard ratios (HRs) for survival with 95% confidence intervals (CIs), subgroup analysis, sensitivity analysis, and publication bias were conducted. RESULTS: 11 studies covering a total of 2943 patients were included. Pooled hazard ratios (HRs) revealed that the presence of CPCs predicted aggressive disease progression (HR = 1.78, 95% CI = 1.57–2.03) and reduced overall survival (OS) (HR = 1.82, 95% CI = 1.59–2.08). Subgroup analyses demonstrated that CPCs positive patients also had poor disease progression and OS in detection methods and sampling time subsets. Moreover, the presence of CPCs was strikingly associated with increased ISS stage (OR = 2.78% CI = 1.69–4.56), but not with DS stage(OR = 1.60; 95% CI = 0.74–3.47). CONCLUSIONS: CPCs status is associated with poorer survival outcome in multiple myeloma. Additionally, increased ISS stage could be significant risk factors for the presence of CPCs.
format Online
Article
Text
id pubmed-5509371
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55093712017-08-07 Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis Li, Jia Wang, Ningning Tesfaluul, Nahom Gao, Xiaojuan Liu, Shuai Yue, Baohong PLoS One Research Article PURPOSE: The clinical significance and prognostic role of circulating plasma cells (CPCs) in multiple myeloma (MM) are still controversial. We conducted the first meta-analysis to clarify the correlation between CPCs and the clinicopathological features and prognosis of MM patients. METHODS: A comprehensive literary search for relevant studies was performed on PubMed, Embase, Medline, CNKI (Chinese) and Web of Science databases (January 1, 1950 to December 20, 2016). The associations between CPCs and survival rate and clinicopathological parameters, including International staging system (ISS) and Durie-Salm staging system (DS) stage, were evaluated. Then pooled hazard ratios (HRs) for survival with 95% confidence intervals (CIs), subgroup analysis, sensitivity analysis, and publication bias were conducted. RESULTS: 11 studies covering a total of 2943 patients were included. Pooled hazard ratios (HRs) revealed that the presence of CPCs predicted aggressive disease progression (HR = 1.78, 95% CI = 1.57–2.03) and reduced overall survival (OS) (HR = 1.82, 95% CI = 1.59–2.08). Subgroup analyses demonstrated that CPCs positive patients also had poor disease progression and OS in detection methods and sampling time subsets. Moreover, the presence of CPCs was strikingly associated with increased ISS stage (OR = 2.78% CI = 1.69–4.56), but not with DS stage(OR = 1.60; 95% CI = 0.74–3.47). CONCLUSIONS: CPCs status is associated with poorer survival outcome in multiple myeloma. Additionally, increased ISS stage could be significant risk factors for the presence of CPCs. Public Library of Science 2017-07-13 /pmc/articles/PMC5509371/ /pubmed/28704521 http://dx.doi.org/10.1371/journal.pone.0181447 Text en © 2017 Li et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Li, Jia
Wang, Ningning
Tesfaluul, Nahom
Gao, Xiaojuan
Liu, Shuai
Yue, Baohong
Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis
title Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis
title_full Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis
title_fullStr Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis
title_full_unstemmed Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis
title_short Prognostic value of circulating plasma cells in patients with multiple myeloma: A meta-analysis
title_sort prognostic value of circulating plasma cells in patients with multiple myeloma: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509371/
https://www.ncbi.nlm.nih.gov/pubmed/28704521
http://dx.doi.org/10.1371/journal.pone.0181447
work_keys_str_mv AT lijia prognosticvalueofcirculatingplasmacellsinpatientswithmultiplemyelomaametaanalysis
AT wangningning prognosticvalueofcirculatingplasmacellsinpatientswithmultiplemyelomaametaanalysis
AT tesfaluulnahom prognosticvalueofcirculatingplasmacellsinpatientswithmultiplemyelomaametaanalysis
AT gaoxiaojuan prognosticvalueofcirculatingplasmacellsinpatientswithmultiplemyelomaametaanalysis
AT liushuai prognosticvalueofcirculatingplasmacellsinpatientswithmultiplemyelomaametaanalysis
AT yuebaohong prognosticvalueofcirculatingplasmacellsinpatientswithmultiplemyelomaametaanalysis